BioNTech, Bristol Myers Report Pumitamig Results in Lung Cancer Trial
The combination produced a 36.7% confirmed response rate and median progression-free survival of 6.9 months in an early Phase 2 study.
Makkler Newsroom · Oct 25, 10:55 AM · 1 min read